OR WAIT null SECS
October 04, 2021
Thermo Fisher’s new Swiss facility will initially produce CSL Limited’s recombinant factor IX product Idelvion.
The expansion to SGS’s Poitiers facility in France is expected to improve the company’s drug development capabilities.
September 30, 2021
In September, Codex DNA released a full-length synthetic genome for the SARS-CoV-2 delta variant, which may accelerate discovery and development of diagnostics and treatments for COVID-19.
The new LabVantage Enterprise SaaS adds full configurability and custom interfacing capabilities.
NewAge Industries has completed a plant expansion that added new cleanrooms to its headquarters in Southampton, Pa.
Gyros’ new titer kit identifies adeno-associated virus serotype 9 in vector-based cell and gene therapy manufacturing.
September 29, 2021
CuriRx’s CuriLytics platform is a mass spectrometry instrument that will support complex biotherapeutics development.
KSL Biomedical announced their expansion into Canada with the acquisition of Pulse Scientific and the incorporation of KSL Biomedical Canada.
September 24, 2021
Celltrion Group has been granted approval for regdanvimab (CT-P59) to be used as a treatment for COVID-19 by the Korean Ministry of Food and Drug Safety (MFDS).
September 23, 2021
The research collaboration between AstraZeneca and VaxEquity aims to discover and develop self-amplifying RNA therapeutics.